雌激素受体β表达与ERalpha-negative乳腺癌三苯氧胺反应。
文章的细节
-
引用
复制到剪贴板 -
Gruvberger-Saal SK,萨尔Bendahl PO, LH, Laakso M, Hegardt C,伊甸园P,彼得森C,表示P,伊索拉J, Borg, Ferno M
雌激素受体β表达与ERalpha-negative乳腺癌三苯氧胺反应。
癌症研究杂志2007年4月1日,13 (7):1987 - 94。
- PubMed ID
-
17404078 (在PubMed]
- 文摘
-
目的:内分泌疗法,如他莫昔芬,通常给大多数患者雌激素受体(ERalpha)阳性乳腺癌但不表示用于ERalpha-negative癌症的人。负责应对它莫西芬的因素在5%到10%的患者ERalpha-negative肿瘤尚不清楚。本研究的目的是阐明第二的生物学和预后作用,辅助患者ERbeta,它莫西芬。实验设计:我们在353年通过免疫组织化学方法研究ERbeta II期乳腺肿瘤患者从2年辅助他莫昔芬和生成的肿瘤基因表达谱在88年代表的子集。结果:ERbeta增加生存(遥远的无病生存,P = 0.01;总体生存,P = 0.22),特别是在ERalpha-negative患者(P = 0.003;P = 0.04),但不是ERalpha-positive子组(P = 0.49;P = 0.88)。缺乏ERbeta授予早期复发(危害比14;95%置信区间,1.8 -106; P = 0.01) within the ERalpha-negative subgroup even after adjustment for other markers. ERalpha was an independent marker only within the ERbeta-negative tumors (hazard ratio, 0.44; 95% confidence interval, 0.21-0.89; P = 0.02). An ERbeta gene expression profile was identified and was markedly different from the ERalpha signature. CONCLUSION: Expression of ERbeta is an independent marker for favorable prognosis after adjuvant tamoxifen treatment in ERalpha-negative breast cancer patients and involves a gene expression program distinct from ERalpha. These results may be highly clinically significant, because in the United States alone, approximately 10,000 women are diagnosed annually with ERalpha-negative/ERbeta-positive breast carcinoma and may benefit from adjuvant tamoxifen.